BioAge Labs (NASDAQ:BIOA) Cut to Sell at Wall Street Zen

BioAge Labs (NASDAQ:BIOA) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

Other equities research analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioAge Labs in a research report on Thursday, October 30th. Citigroup lifted their target price on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $15.00.

BioAge Labs Price Performance

Shares of NASDAQ BIOA opened at $14.03 on Friday. The company’s 50 day moving average price is $10.90. BioAge Labs has a 52-week low of $2.88 and a 52-week high of $16.43. The firm has a market capitalization of $502.98 million, a PE ratio of -9.23 and a beta of 1.38.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Thursday, November 6th. The company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.11. The firm had revenue of $2.05 million during the quarter.

Insider Transactions at BioAge Labs

In related news, insider Paul D. Rubin sold 68,897 shares of the stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $10.19, for a total value of $702,060.43. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 20.82% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio bought a new position in shares of BioAge Labs in the second quarter worth $57,000. Geode Capital Management LLC lifted its holdings in BioAge Labs by 60.8% in the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock worth $1,873,000 after purchasing an additional 171,426 shares during the period. Police & Firemen s Retirement System of New Jersey bought a new position in BioAge Labs in the 2nd quarter valued at about $27,000. Intech Investment Management LLC bought a new position in BioAge Labs in the 2nd quarter valued at about $60,000. Finally, Jefferies Financial Group Inc. acquired a new position in BioAge Labs during the 2nd quarter valued at about $206,000.

BioAge Labs Company Profile

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.